ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 275 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,254,679 | -20.0% | 77,211 | -8.9% | 0.00% | 0.0% |
Q1 2024 | $1,567,878 | -48.0% | 84,796 | -11.9% | 0.00% | -50.0% |
Q4 2023 | $3,012,461 | +85.0% | 96,214 | +23.1% | 0.00% | +100.0% |
Q3 2023 | $1,628,437 | +7.6% | 78,140 | +23.7% | 0.00% | 0.0% |
Q2 2023 | $1,513,210 | +20.5% | 63,182 | -5.3% | 0.00% | 0.0% |
Q1 2023 | $1,255,915 | +5.2% | 66,733 | -11.0% | 0.00% | 0.0% |
Q4 2022 | $1,193,571 | +10.4% | 74,973 | +13.4% | 0.00% | 0.0% |
Q3 2022 | $1,081,000 | -35.2% | 66,098 | -44.2% | 0.00% | 0.0% |
Q2 2022 | $1,668,000 | +70.7% | 118,403 | +193.4% | 0.00% | 0.0% |
Q1 2022 | $977,000 | +6.1% | 40,349 | +2.2% | 0.00% | 0.0% |
Q4 2021 | $921,000 | -4.2% | 39,465 | -31.8% | 0.00% | 0.0% |
Q3 2021 | $961,000 | -29.8% | 57,843 | +3.1% | 0.00% | 0.0% |
Q2 2021 | $1,368,000 | +10.1% | 56,084 | +16.4% | 0.00% | 0.0% |
Q1 2021 | $1,243,000 | -49.5% | 48,191 | +4.6% | 0.00% | -50.0% |
Q4 2020 | $2,463,000 | +27.7% | 46,080 | -1.4% | 0.00% | 0.0% |
Q3 2020 | $1,928,000 | -29.7% | 46,726 | -17.4% | 0.00% | 0.0% |
Q2 2020 | $2,743,000 | -1.2% | 56,585 | -13.9% | 0.00% | -33.3% |
Q1 2020 | $2,775,000 | +2.4% | 65,684 | +3.7% | 0.00% | +50.0% |
Q4 2019 | $2,709,000 | -19.9% | 63,319 | -32.6% | 0.00% | -33.3% |
Q3 2019 | $3,382,000 | +47.9% | 93,965 | +9.8% | 0.00% | +50.0% |
Q2 2019 | $2,287,000 | +160.2% | 85,587 | +161.6% | 0.00% | +100.0% |
Q1 2019 | $879,000 | +75.1% | 32,718 | +5.4% | 0.00% | 0.0% |
Q4 2018 | $502,000 | -36.5% | 31,051 | -18.4% | 0.00% | 0.0% |
Q3 2018 | $790,000 | +56.7% | 38,054 | +15.3% | 0.00% | – |
Q2 2018 | $504,000 | -35.1% | 32,997 | -4.6% | 0.00% | -100.0% |
Q1 2018 | $777,000 | -21.4% | 34,585 | +5.3% | 0.00% | 0.0% |
Q4 2017 | $989,000 | +97.0% | 32,853 | +146.5% | 0.00% | – |
Q3 2017 | $502,000 | +7.0% | 13,329 | -20.7% | 0.00% | – |
Q2 2017 | $469,000 | -15.9% | 16,810 | +3.6% | 0.00% | -100.0% |
Q1 2017 | $558,000 | +11.6% | 16,231 | -6.3% | 0.00% | 0.0% |
Q4 2016 | $500,000 | -21.6% | 17,323 | -13.6% | 0.00% | 0.0% |
Q3 2016 | $638,000 | +3.4% | 20,045 | +5.4% | 0.00% | 0.0% |
Q2 2016 | $617,000 | +48.7% | 19,013 | +28.1% | 0.00% | 0.0% |
Q1 2016 | $415,000 | -15.1% | 14,843 | +8.3% | 0.00% | 0.0% |
Q4 2015 | $489,000 | +7.9% | 13,706 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $453,000 | -2.4% | 13,706 | +23.8% | 0.00% | 0.0% |
Q2 2015 | $464,000 | +23.1% | 11,072 | -4.3% | 0.00% | 0.0% |
Q1 2015 | $377,000 | +1.3% | 11,568 | -1.3% | 0.00% | 0.0% |
Q4 2014 | $372,000 | +11.4% | 11,716 | -13.1% | 0.00% | 0.0% |
Q3 2014 | $334,000 | +9.5% | 13,483 | 0.0% | 0.00% | 0.0% |
Q2 2014 | $305,000 | -31.2% | 13,483 | -25.9% | 0.00% | 0.0% |
Q1 2014 | $443,000 | -14.1% | 18,192 | -11.9% | 0.00% | 0.0% |
Q4 2013 | $516,000 | -9.0% | 20,650 | 0.0% | 0.00% | 0.0% |
Q3 2013 | $567,000 | +42.1% | 20,650 | -6.1% | 0.00% | 0.0% |
Q2 2013 | $399,000 | – | 22,003 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 647,833 | $26,723,000 | 11.32% |
GREAT POINT PARTNERS LLC | 1,921,563 | $79,264,000 | 7.13% |
Baker Brothers Advisors | 41,904,586 | $1,728,564,000 | 6.91% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 486,000 | $20,048,000 | 6.47% |
Palo Alto Investors LP | 1,832,300 | $75,582,000 | 4.15% |
Birchview Capital, LP | 204,000 | $8,416,000 | 2.81% |
SECTORAL ASSET MANAGEMENT INC | 556,514 | $22,956,000 | 1.97% |
Rock Springs Capital Management LP | 1,573,200 | $64,895,000 | 1.65% |
Riggs Asset Managment Co. Inc. | 17,470 | $2,025,000 | 0.85% |
PFM Health Sciences, LP | 421,087 | $17,370,000 | 0.80% |